Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2019
Randomized Controlled Trial Multicenter StudyA randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease. ⋯ Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis.
-
J. Am. Acad. Dermatol. · Apr 2019
Randomized Controlled Trial Multicenter StudyTezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of atopic dermatitis (AD). ⋯ Although not statistically significant, numerical improvements over placebo for all week 12 endpoints were demonstrated, with greater week 16 responses.
-
J. Am. Acad. Dermatol. · Apr 2019
Randomized Controlled TrialBaricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling. ⋯ Baricitinib used with TCSs reduced inflammation and pruritus in patients with moderate-to-severe AD.
-
J. Am. Acad. Dermatol. · Jan 2019
Randomized Controlled Trial Comparative StudyIxekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile. ⋯ Compared with ustekinumab, ixekizumab showed superior efficacy and comparable safety outcomes through 52 weeks of treatment.
-
J. Am. Acad. Dermatol. · Nov 2018
Randomized Controlled Trial Multicenter StudyMaintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis. ⋯ IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years.